Prosecution Insights
Last updated: October 04, 2026

Duane Morris LLP - Ny

Technology area: Biotechnology & Pharmaceuticals

28 pending office actions • 9 clients • 27 examiners • 14 art units • 0 of 28 (0%) have an AI response strategy ready • 58 patents granted in the last 365 days

Analysis

DUANE MORRIS LLP - NY is a patent law firm with a primary focus on Biotechnology & Pharmaceuticals. The firm has a career total of 13323 applications, demonstrating a high level of experience in the patent system. It has achieved a resolved allowance rate of 87.79 percent, reflecting a strong performance in obtaining allowances for its clients. This track record is significant given the complexities of the Biotechnology & Pharmaceuticals sector. The firm's large portfolio provides a robust basis for performance analysis.

The NY office currently has 26 pending office actions. Its prosecution process involves an average of 3.37 office actions per allowance. This statistic helps set expectations for the duration and complexity of the examination phase. With 13323 career applications and an 87.79 percent allowance rate, the firm shows a consistent track record. The 3.37 average office actions per allowance provides a specific metric for evaluating the firm's efficiency in Biotechnology & Pharmaceuticals. These data points are essential for understanding the firm's impact in New York.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=13323 apps, methodology: how we score firms)

87.8%
Allowance Rate
n=13323
+0.66σ
Allowance Rate (norm)
n=13323
3.4
OAs to Allowance
n=8373
-0.17σ
OAs to Allow (norm)
n=8373
1055 days
Time to Allowance
n=8373
+8.4pp
Interview Lift
n=13323
25.9%
RCE Rate
n=13323
1.6%
Appeal Rate
n=13323

Rejection Performance (% of received rejections ultimately overcome)

79.4%
§101 Overcome
n=1039
80.9%
§102 Overcome
n=3470
81.8%
§103 Overcome
n=5508
82.9%
§112 Overcome
n=4611

Specialization & Scale

H10K, C07F, A61B
Top CPC Subclasses
14%
Top-3 CPC Share
n=13323
0
Practitioners
n=13323
—
Apps / Practitioner
n=13323 (min 20)

Portfolio Summary

28
Total Pending OAs
21
Non-Final OAs
7
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

9
Overdue
1
Due this week
0
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (9)Due ≤ 7 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

13
Hard (46%)
8
Medium (29%)
7
Easy (25%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other5 (18%)
§103 only4 (14%)
§102 only1 (4%)
§112 only6 (21%)
Double-patenting only1 (4%)
Double-patenting + other3 (11%)
Multi-statute (no §101)8 (29%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

21
Life Sciences
75% of docket
0
Information Tech
0% of docket
1
Communications
4% of docket
1
Semiconductors
4% of docket
2
Mechanical / Eng
7% of docket
3
Business / Other
11% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

280 h
Manual time on pending OAs
56 h
Time saved (low, 20%)
98 h
Time saved (mid, 35%)
2.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
IBRAHIM, MEDINA AHMED 2 87.4% +12.2%
KUMAR, VINOD 1 82.7% +20.4%
ZHENG, LI 1 83.6% +12.9%
STEPHENS, REBECCA JOHANNA 1 67.3% +29.3%
SHEN, YANXIN NMN 1 90.0% +22.5%
STOCKDALE, JESSICA NICOLE 1 50.0% +35.2%
SULLIVAN, BRIAN JAMES 1 76.9% +14.4%
LOGSDON, CHARLES 1 71.7% +11.2%
TRAN, CHRISTINA L 1 51.6% +48.2%
BLUMEL, BENJAMIN P 1 70.8% +30.5%

Quick Wins (4)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18631696 BRASSICA PLANT RESISTANT TO DOWNY MILDEW IBRAHIM, MEDINA AHMED 30d overdue
19327595 CULTIVATED ROCKET VARIETY 88-CR31134 RZ IBRAHIM, MEDINA AHMED —
19326034 CULTIVATED ROCKET VARIETY 88-CR31138 RZ KUMAR, VINOD —
19052708 BROCCOLI VARIETY 25-BO239 RZ ZHENG, LI —

Hard Cases (13)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18673456 ALBUGO CANDIDA RESISTANCE GENE DELEO, VICTORIA LYNN 103d overdue
18240461 TRAINING OF INSTANT SEGMENTATION ALGORITHMS WITH PARTIALLY ANNOTATED IMAGES LU, ZHIYU 44d overdue
17875549 CMV RESISTANCE CONFERRING GENES CHATTERJEE, JAYANTA 6d
18923953 PERONOSPORA RESISTANCE IN SPINACIA OLERACEA SHEN, YANXIN NMN —
18797867 MODIFIED GENE FOR MORE EFFICIENT CULTIVATION OF CUCUMBER STOCKDALE, JESSICA NICOLE —
18774411 MODIFIED TOM2A GENE INVOLVED IN TOBAMOVIRUS RESISTANCE LOGSDON, CHARLES —
18715360 NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS BLUMEL, BENJAMIN P —
18713340 VEGAN-BASED EGG YOLK SUBSTITUTE PRODUCT DIOU BERDECIA, LUIS EUGENIO —

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17371357 CMI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER, ATHEROSCLEROSIS, DIABETES AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES TRAN, CHRISTINA L 79d overdue
18631696 BRASSICA PLANT RESISTANT TO DOWNY MILDEW IBRAHIM, MEDINA AHMED 30d overdue
18798341 HYBRID TOMATO VARIETY 72-MP0030 RZ SULLIVAN, BRIAN JAMES 8d overdue
19327595 CULTIVATED ROCKET VARIETY 88-CR31134 RZ IBRAHIM, MEDINA AHMED —
19326034 CULTIVATED ROCKET VARIETY 88-CR31138 RZ KUMAR, VINOD —
19052708 BROCCOLI VARIETY 25-BO239 RZ ZHENG, LI —
19033739 CYSDV RESISTANCE IN MEMBERS OF THE CUCURBITACEAE FAMILY STEPHENS, REBECCA JOHANNA —
18923953 PERONOSPORA RESISTANCE IN SPINACIA OLERACEA SHEN, YANXIN NMN —

Client Portfolio (9 clients)

Top Art Units

Art UnitApps
16627
16636
16371
17921
17931
36431
16241
37961
16411
26651

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19327595 CULTIVATED ROCKET VARIETY 88-CR31134 RZ Rijk Zwaan Zaadteelt En Zaadhandel B.V. IBRAHIM, MEDINA AHMED 1662 §112 Non-Final OA — Pending Sep 12, 2025
19326034 CULTIVATED ROCKET VARIETY 88-CR31138 RZ Rijk Zwaan Zaadteelt En Zaadhandel B.V. KUMAR, VINOD 1663 §112 Non-Final OA — Pending Sep 11, 2025
19052708 BROCCOLI VARIETY 25-BO239 RZ Rijk Zwaan Zaadteelt En Zaadhandel B.V. ZHENG, LI §112 Non-Final OA — Pending Feb 13, 2025
19033739 CYSDV RESISTANCE IN MEMBERS OF THE CUCURBITACEAE FAMILY Rijk Zwaan Zaadteelt En Zaadhandel B.V. STEPHENS, REBECCA JOHANNA 1663 DP Non-Final OA — Pending Jan 22, 2025
18923953 PERONOSPORA RESISTANCE IN SPINACIA OLERACEA Rijk Zwaan Zaadteelt En Zaadhandel B.V. SHEN, YANXIN NMN 1663 §101§112 Non-Final OA — Pending Oct 23, 2024
18797867 MODIFIED GENE FOR MORE EFFICIENT CULTIVATION OF CUCUMBER Rijk Zwaan Zaadteelt En Zaadhandel B.V. STOCKDALE, JESSICA NICOLE 1663 §102§112 Non-Final OA — Pending Aug 08, 2024
18798341 HYBRID TOMATO VARIETY 72-MP0030 RZ Rijk Zwaan Zaadteelt En Zaadhandel B.V. SULLIVAN, BRIAN JAMES 1663 §112 Non-Final OA 8d overdue Pending Aug 08, 2024
18774411 MODIFIED TOM2A GENE INVOLVED IN TOBAMOVIRUS RESISTANCE Rijk Zwaan Zaadteelt En Zaadhandel B.V. LOGSDON, CHARLES 1662 §102§103§112 Non-Final OA — Pending Jul 16, 2024
17371357 CMI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER, ATHEROSCLEROSIS, DIABETES AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS TRAN, CHRISTINA L 1637 §112 Final Rejection 79d overdue Pending Jul 09, 2024
18715360 NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS UNIVERSITÄT ZU KÖLN BLUMEL, BENJAMIN P §101§112 Non-Final OA — Pending May 31, 2024
18678050 HIGH SENSITIVITY AND RAPID NUCLEIC ACID DETECTION Git Applied Biotechnologies, Llc. CROW, ROBERT THOMAS §103 Non-Final OA — Pending May 30, 2024
18673456 ALBUGO CANDIDA RESISTANCE GENE Rijk Zwaan Zaadteelt En Zaadhandel B.V. DELEO, VICTORIA LYNN 1662 §101§102§103§112 Non-Final OA 103d overdue Pending May 24, 2024
18713340 VEGAN-BASED EGG YOLK SUBSTITUTE PRODUCT Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. DIOU BERDECIA, LUIS EUGENIO 1792 §103§112 Non-Final OA — Pending May 24, 2024
18713281 USE OF A THERMOPLASTIC, BIOBASED AND BIODEGRADABLE MATERIAL HAVING BRITTLE FRACTURE MECHANICS AS A SHELL FOR AN EGG OR EGG-REPLACEMENT PRODUCT, AND VEGAN EGG-REPLACEMENT PRODUCT ENCASED BY SUCH A SHELL Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. SALAMON, PETER A 1793 §102§112 Non-Final OA — Pending May 24, 2024
18631246 METHOD FOR CHANGING THE INTERCELLULAR MOBILITY OF AN MRNA Rijk Zwaan Zaadteelt En Zaadhandel B.V. DEVEAU ROSEN, JASON 1662 §112DP Final Rejection 22d overdue Pending Apr 10, 2024
18631696 BRASSICA PLANT RESISTANT TO DOWNY MILDEW Rijk Zwaan Zaadteelt En Zaadhandel B.V. IBRAHIM, MEDINA AHMED 1662 §103§112DP Final Rejection 30d overdue Pending Apr 10, 2024
18621666 VEGETABLES, MUSHROOMS OR HERBS IN A BOX Rijk Zwaan Zaadteelt En Zaadhandel B.V. NGUYEN, SON T 3643 §103 Final Rejection 46d overdue Pending Mar 29, 2024
18683412 PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE UCL Business Ltd HABTE, KAHSAY 1624 §112Other Non-Final OA — Pending Feb 13, 2024
18422869 SYSTEMS AND METHODS FOR OPTIMIZING USE OF A MEDICAL DEVICE FOR PAIN MANAGEMENT Biowave Corporation STICE, PAULA J 3796 §103 Final Rejection 63d Pending Jan 25, 2024
18459879 CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1 DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS WEN, SHARON X 1641 §102§103 Non-Final OA — Pending Sep 01, 2023
18240461 TRAINING OF INSTANT SEGMENTATION ALGORITHMS WITH PARTIALLY ANNOTATED IMAGES Carl Zeiss Microscopy GmbH LU, ZHIYU 2665 §101§103 Final Rejection 44d overdue Pending Aug 31, 2023
18339316 ILLUMINATION DEVICE AND MICROSCOPY METHOD FOR GENERATING A COMPOSITE IMAGE OF A SAMPLE Carl Zeiss Microscopy GmbH ABDUR, RAHMAN 2872 §103 Non-Final OA 149d overdue Pending Jun 22, 2023
18252672 PROGRAMMABLE NANO-REACTORS FOR STOCHASTIC SENSING (PNRSS) Nanjing University MUMMERT, STEPHANIE KANE 1681 §102 Non-Final OA — Pending May 11, 2023
18306580 PERONOSPORA RESISTANCE IN SPINACIA OLERACEA Rijk Zwaan Zaadteelt En Zaadhandel B.V. BOGGS, RUSSELL T 1663 §101§102§112DP Non-Final OA — Pending Apr 25, 2023
18163503 RESISTANCE GENES AND PLANTS RESISTANT TO BEGOMOVIRUSES Rijk Zwaan Zaadteelt En Zaadhandel B.V. RADOSAVLJEVIC, ALEKSANDAR 1662 §102§112 Non-Final OA — Pending Feb 02, 2023
17904393 AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE 2 UCL Business PLC WELLS, LAUREN QUINLAN 1622 §112DP Non-Final OA 87d overdue Pending Aug 17, 2022
17904388 AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE UCL Business Ltd MCMILLIAN, KARA RENITA 1623 §102§112Other Non-Final OA — Pending Aug 17, 2022
17875549 CMV RESISTANCE CONFERRING GENES Rijk Zwaan Zaadteelt En Zaadhandel B.V. CHATTERJEE, JAYANTA 1662 §102§103§112 Final Rejection 6d Pending Jul 28, 2022

Managing Duane Morris LLP - Ny's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month